Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Levonorgestrel / Ethinyl Estradiol and Ethinyl Estradiol

&times

Overview

What is Seasonique?

Seasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) is an extended-cycle oral contraceptive consisting of 84 light blue-green tablets each containing 0.15 mg of levonorgestrel, a synthetic progestogen and 0.03 mg of ethinyl estradiol, and 7 yellow tablets containing 0.01 mg of ethinyl estradiol.

The structural formulas for the active components are:

Levonorgestrel

CHO MW: 312.4

Levonorgestrel is chemically 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-, (-)-.

Ethinyl Estradiol

CHO MW: 296.4

Ethinyl Estradiol is 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-.

Each light blue-green tablet contains the following inactive ingredients

Each yellow tablet contains the following inactive ingredients



What does Seasonique look like?



What are the available doses of Seasonique?

Seasonique consists of 84 light blue-green tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, and 7 yellow tablets containing 0.01 mg ethinyl estradiol. ()

What should I talk to my health care provider before I take Seasonique?

How should I use Seasonique?

Seasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) is indicated for use by women to prevent pregnancy.

Take one tablet by mouth at the same time every day. The dosage of Seasonique is one light blue-green tablet containing levonorgestrel and ethinyl estradiol daily for 84 consecutive days, followed by one yellow ethinyl estradiol tablet for 7 days. To achieve maximum contraceptive effectiveness, Seasonique must be taken exactly as directed and at intervals not exceeding 24 hours.

Instruct the patient to begin taking Seasonique on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first light blue-green tablet is taken that day. One light blue-green tablet should be taken daily for 84 consecutive days, followed by one yellow tablet for 7 consecutive days. A non-hormonal back-up method of contraception (such as condoms or spermicide) should be used until a light blue-green tablet has been taken daily for 7 consecutive days. A scheduled period should occur during the 7 days that the yellow tablets are taken.

Begin the next and all subsequent 91-day cycles without interruption on the same day of the week (Sunday) on which the patient began her first dose of Seasonique, following the same schedule: 84 days taking a light blue-green tablet followed by 7 days taking a yellow tablet. If the patient does not immediately start her next pill pack, she should protect herself from pregnancy by using a non-hormonal back-up method of contraception until she has taken a light blue-green tablet daily for 7 consecutive days.

If unscheduled spotting or bleeding occurs, instruct the patient to continue on the same regimen. If the bleeding is persistent or prolonged, advise the patient to consult her healthcare provider.

For patient instructions regarding missed pills, see .

For postpartum women who are not breastfeeding, start Seasonique no earlier than four to six weeks postpartum due to increased risk of thromboembolism. If the patient starts on Seasonique postpartum and has not yet had a period, evaluate for possible pregnancy, and instruct her to use an additional method of contraception until she has taken a light blue-green tablet for 7 consecutive days.


What interacts with Seasonique?

Sorry No Records found


What are the warnings of Seasonique?

Sorry No Records found


What are the precautions of Seasonique?

Sorry No Records found


What are the side effects of Seasonique?

Sorry No records found


What should I look out for while using Seasonique?

Do not prescribe Seasonique to women who are known to have the following:


What might happen if I take too much Seasonique?

There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.


How should I store and handle Seasonique?

Store at 20° to 25° C (68° to 77° F) [See USP Controlled Room Temperature].ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17ENDOCET (Oxycodone and Acetaminophen Tablets, USP) is supplied as follows:2.5 mg/325 mg Pink, oval, tablet, debossed with “E701” on one side and “2.5” on the other. Bottles of 100                                  NDC 60951-701-705 mg/325 mg White, round, tablet, with one face scored and the other inscribed "Endo" and "602". Bottles of 100                                  NDC 60951-602-70 Bottles of 500                                  NDC 60951-602-85 7.5 mg/325 mg Peach, oval-shaped, tablet, debossed with “ E700” on one side and “7.5/325” on the other. Bottles of 100                                  NDC 60951-700-70 10 mg/325 mg Yellow, capsule-shaped, tablet, debossed with “E712” on one side and “10/325” on the other. Bottles of 100                                  NDC 60951-712-70 StorageStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required.Distributed by: Chestnut Ridge, NY 10977ENDOCET is a registered trademark of Endo Pharmaceuticals Inc.© 2017 Endo Pharmaceuticals Inc. All rights reserved.Printed in U.S.A.8183403 R8Revised: 3/17


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology
Do not prescribe Seasonique to women who are known to have the following:





After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease [see ], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to ENDOCET.

If concomitant use is necessary, consider dosage reduction of ENDOCET until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals. If a CYP3A4 inhibitor is discontinued, consider increasing the ENDOCET dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.







After stopping a CYP3A4 inducer, as the effects of the inducer decline, the oxycodone plasma concentration will increase [see ], which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.

If concomitant use is necessary, consider increasing the ENDOCET dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider ENDOCET dosage reduction and monitor for signs of respiratory depression.

Benzodiazepines and Other CNS Depressants

Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation [see ].





If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue ENDOCET if serotonin syndrome is suspected.





The use of ENDOCET is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.

If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.

Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics

Advise patient to avoid concomitant use of these drugs.

Muscle Relaxants

If concomitant use is warranted, monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of ENDOCET and/or the muscle relaxant as necessary.

Diuretics

If concomitant use is warranted, monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.

Anticholinergic Drugs

If concomitant use is warranted, monitor patients for signs of urinary retention or reduced gastric motility when ENDOCET is used concomitantly with anticholinergic drugs.

Alcohol, ethyl

Oral Contraceptives

Charcoal (activated)

Beta Blockers (Propranolol)

Loop Diuretics

Lamotrigine

Probenecid

Zidovudine

Stop Seasonique if an arterial or deep venous thrombotic event occurs. Although the use of COCs increases the risk of venous thromboembolism, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs. The risk of venous thromboembolism in women using COCs is 3 to 9 per 10,000 woman-years. The excess risk is highest during the first year of use of a COC. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. The risk of thromboembolic disease due to COCs gradually disappears after COC use is discontinued.

Use of Seasonique provides women with more hormonal exposure on a yearly basis than conventional monthly oral contraceptives containing the same strength synthetic estrogens and progestins (an additional 9 and 13 weeks of exposure to progestin and estrogen, respectively, per year).

If feasible, stop Seasonique at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism.

Start Seasonique no earlier than 4-6 weeks after delivery, in women who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.

COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), and hypertensive women who also smoke. COCs also increase the risk for stroke in women with other underlying risk factors.

Oral contraceptives must be used with caution in women with cardiovascular disease risk factors.

Stop Seasonique if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.

The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:

Adverse reactions commonly reported by COC users are:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).